NO20004363D0 - Anvendelse av D1-/D5-antagonister for behandling av tvangsforstyrrelser, somatoforme forstyrrelser, dissosiative forstyrrelser, impulskontroll forstyrrelser og autisme - Google Patents

Anvendelse av D1-/D5-antagonister for behandling av tvangsforstyrrelser, somatoforme forstyrrelser, dissosiative forstyrrelser, impulskontroll forstyrrelser og autisme

Info

Publication number
NO20004363D0
NO20004363D0 NO20004363A NO20004363A NO20004363D0 NO 20004363 D0 NO20004363 D0 NO 20004363D0 NO 20004363 A NO20004363 A NO 20004363A NO 20004363 A NO20004363 A NO 20004363A NO 20004363 D0 NO20004363 D0 NO 20004363D0
Authority
NO
Norway
Prior art keywords
disorders
autism
obsessive
antagonists
treatment
Prior art date
Application number
NO20004363A
Other languages
English (en)
Other versions
NO20004363L (no
Inventor
Vicki L Coffin
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20004363D0 publication Critical patent/NO20004363D0/no
Publication of NO20004363L publication Critical patent/NO20004363L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20004363A 1998-03-02 2000-09-01 Anvendelse av D1-/D5-antagonister for behandling av tvangsforstyrrelser, somatoforme forstyrrelser, dissosiative forstyrrelser, impulskontrollforstyrrelser og autisme NO20004363L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3320598A 1998-03-02 1998-03-02
PCT/US1999/003721 WO1999044615A1 (en) 1998-03-02 1999-03-01 Use of d1/d5 antagonists for treating obsessive compulsive disorders, somatoform disorders, dissociative, eating disorders, impulse control disorders and autism

Publications (2)

Publication Number Publication Date
NO20004363D0 true NO20004363D0 (no) 2000-09-01
NO20004363L NO20004363L (no) 2000-10-31

Family

ID=21869083

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004363A NO20004363L (no) 1998-03-02 2000-09-01 Anvendelse av D1-/D5-antagonister for behandling av tvangsforstyrrelser, somatoforme forstyrrelser, dissosiative forstyrrelser, impulskontrollforstyrrelser og autisme

Country Status (16)

Country Link
EP (1) EP1058551A1 (no)
JP (1) JP2002505291A (no)
KR (1) KR20010041477A (no)
CN (1) CN1291893A (no)
AR (1) AR018297A1 (no)
AU (1) AU2778099A (no)
BR (1) BR9908392A (no)
CA (1) CA2322201A1 (no)
CO (1) CO4910136A1 (no)
HU (1) HUP0101057A3 (no)
IL (1) IL137715A0 (no)
NO (1) NO20004363L (no)
PE (1) PE20000333A1 (no)
SK (1) SK12962000A3 (no)
WO (1) WO1999044615A1 (no)
ZA (1) ZA991638B (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410527B1 (en) * 1998-03-02 2002-06-25 Schering Corporation Method of treating obsessive compulsive disorders, somatoform disorders, dissociative disorders, eating disorders, impulse control disorders, and autism
RU2374245C1 (ru) 2008-08-22 2009-11-27 Андрей Александрович Иващенко Лиганд с широким спектром одновременной рецепторной активности, фармацевтическая композиция, способ ее получения и лекарственное средство
PL3919060T3 (pl) * 2012-07-12 2025-10-20 Emalex Biosciences, Inc. Ekopipam do leczenia zespołu tourette'a

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605897A (en) * 1991-04-23 1997-02-25 Eli Lilly And Company 2-methyl-thieno-benzodiazepine
IL135659A0 (en) * 1997-10-28 2001-05-20 Schering Corp Method of reducing craving in mammals

Also Published As

Publication number Publication date
AU2778099A (en) 1999-09-20
IL137715A0 (en) 2001-10-31
ZA991638B (en) 1999-09-01
HUP0101057A3 (en) 2001-09-28
NO20004363L (no) 2000-10-31
CO4910136A1 (es) 2000-04-24
AR018297A1 (es) 2001-11-14
WO1999044615A1 (en) 1999-09-10
JP2002505291A (ja) 2002-02-19
HUP0101057A2 (hu) 2001-08-28
SK12962000A3 (sk) 2001-08-06
EP1058551A1 (en) 2000-12-13
KR20010041477A (ko) 2001-05-25
BR9908392A (pt) 2000-10-31
PE20000333A1 (es) 2000-05-13
CA2322201A1 (en) 1999-09-10
CN1291893A (zh) 2001-04-18

Similar Documents

Publication Publication Date Title
MXPA03007960A (es) Compuestos y metodos para el tratamiento de desordenes urogenitales.
SI1455785T1 (sl) Substituirani 2-tio-3,5-diciano-4-fenil-6-aminopiridini in njihova uporaba
DK1459750T3 (da) (S,S)-rebexetin til behandling af fibromyalgi og andre somatoforme lidelser
PT2266594E (pt) Vegf para utilização no tratamento de distúrbios do sistema nervoso central
DK1047428T3 (da) Anvendelse af morpholinol til behandlingen af seksualforstyrrelser
NO20012160D0 (no) Anordning for behandling av makulös degenerering
IS5113A (is) Notkun antagónista CB1-viðtaka til meðhöndlunar löngunartruflana
GB0007193D0 (en) Treatment of movrmrnt disorders
NO20043085L (no) Fremgangsmater og sammensetninger for behandling av forstyrrelser i sentralnervesystemet
EP1392292A4 (en) PYRANOINDAZOLES AND THEIR USE IN GLAUCOMA TREATMENT
NO20032636D0 (no) 3-indolinderivater som er nyttige i behandlingen av psykiatriske og nevrologiske forstyrrelser
ZA200107689B (en) 1-Arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of CNS disorders.
IL155589A0 (en) Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
NO20030800L (no) Aminoalkylbenzoyl-benzofuran- eller benzotiofenderivater, fremgangsmåte forderes fremstilling og preparater inneholdende de samme
MXPA01001535A (es) Dispositivo para irradiacion untravioleta para el tratamiento de aguas residuales.
ZA200108856B (en) Treatment of neurotic disorders.
NO20010456L (no) Triazolopyridiner for behandling av trombose lidelser
DK1399424T3 (da) Fremgangsmåde til fremstilling af 10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepin-5-carboxamid og 10,11-dihydro-10-oxo-5H-dibenz[b,f]azepin-5-carboxamid
ZA200205098B (en) Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2-mediated disorders.
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
MXPA03004190A (es) Tratamiento de trastornos de ansiedad.
NO20023803D0 (no) Anvendelse av mirtazapin for behandling av sövnforstyrrelser
NO20004363D0 (no) Anvendelse av D1-/D5-antagonister for behandling av tvangsforstyrrelser, somatoforme forstyrrelser, dissosiative forstyrrelser, impulskontroll forstyrrelser og autisme
AR026062A1 (es) Tratamiento de desordenes oculares
NO20012612D0 (no) Isonipecotamider for behandling av integren-formidlede lidelser